GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PYXIS ONCOLOGY INC

Financial Performance:

• The transcript contains no specific financial metrics (revenue, cash flow, debt, or margins) as this is a clinical-stage biotech company; the company is described as a "small biotech" managing resources judiciously to fund the pivotal trial.
• No revenue is expected immediately, with the primary financial focus on executing the "headliner" Phase 3 trial.

Guidance and Future Outlook:

• Phase 3 (Headliner Trial): Plans to start first-patient-in (FPI) in the pivotal second-line trial in the middle of next year.
• Data Updates:
  • January 2026: End-of-Phase 2 update regarding FDA Project Optimist dose selection and optimization (expected dose: 5.4 mg/kg with cap).
  • December 2025: Updated data for the first-line combination with pembrolizumab (20 patients, doses 3.6 and 4.4, cross-HPV status).
  • H2 2026: Progression-free survival (PFS) and overall survival (OS) data for the second-line program to de-risk the program.
• Regulatory Strategy: Aiming for a full regulatory plan disclosure in early 2027 to support accelerated approval timelines.
• Pipeline Expansion: Potential expansion into breast, lung, pancreatic, and sarcoma cancers contingent on strong clinical signals and standard-of-care potential.

Business Segments and Product Lines:

• Lead Asset (Mikmo/MCBO): A novel ADC targeting the tumor extracellular matrix (ED-BFN), distinct from traditional cell-surface targets.
• Second-Line Head & Neck Cancer (Primary Focus): The immediate priority is establishing the drug as a new standard of care in this setting, where unmet need is high and current options are limited.
• First-Line Combination: Evaluating Mikmo + Pembrolizumab; initial small cohort (N=7) showed a 71% response rate across line settings.
• Biomarker Strategy: Current data suggests the drug is effective regardless of ED-BFN-H scoring or HPV status, supporting a biomarker-agnostic approach.

Market and Competitive Landscape:

• Market Shift: The frontline standard of care in head and neck cancer is rapidly evolving with the approval of EGFR bispecifics (e.g., Amivantamab), which leaves a significant void in second-line treatment options.
• Target Population: Estimates ~20,000 patients in the US seeking second-line treatment annually (derived from ~30,000 first-line patients where 70% seek second-line care).
• Competitive Position: Mikmo demonstrates efficacy regardless of prior therapy (including platinum/PD-1 and EGFR inhibitors), positioning it as a unique option where other options are scarce.

Risks and Challenges:

• Safety Profile: Peripheral neuropathy (PN) is a class effect of the payload; however, management via modified weight-based dosing and dose caps has reduced Grade 3 PN incidence by nearly half.
• Timing Risks: Delays in FPI for the Phase 3 trial or negative data in the December first-line update could hinder progress.
• Resource Constraints: As a small biotech, the company must balance the immediate head-and-neck focus with potential future investments in other tumor types.
• Regulatory Uncertainty: Finalizing the optimal dose (Project Optimist) and defining the exact regulatory pathway for 2027 approval remains a work in progress.

Management Commentary and Tone:

• Confidence: Management expressed high enthusiasm and confidence, citing "profound impact" potential and a "really strong signal" in clinical data.
• Strategic Clarity: Tom Civic emphasized a disciplined approach to resource allocation, focusing 100% on the head-and-neck program to maximize the chance of success before considering partnerships or other indications.
• Collaborative Stance: Management highlighted a constructive and collaborative relationship with the FDA and EMA regarding trial design and dose optimization.

Analyst Questions and Answers:

• Q: How does the drug fit amidst changing frontline standards (e.g., Amivantamab)?
  • A: Mikmo is uniquely positioned for the second-line setting, showing universal efficacy regardless of prior frontline treatments (platinum/PD-1 or EGFR inhibitors).
• Q: What were the key takeaways from the September Phase 1 data?
  • A: 36% overall response rate (ORR), >6 months median PFS, and 79% 12-month OS probability in heavily pretreated patients; safety profile is manageable with dose caps.
• Q: What is the nature of the peripheral neuropathy seen?
  • A: It occurs late (median onset 5.5 months), allowing time for benefit assessment; it is largely reversible upon dose interruption/holiday, with high response rates (67%) even in patients experiencing Grade 3 PN.
• Q: Is an accelerated approval path possible?
  • A: The company is exploring options to expedite delivery to patients, with a full regulatory strategy expected in early 2027, but no definitive acceleration plan was disclosed yet.
• Q: Are there biomarker requirements?
  • A: Current data indicates the drug works regardless of HPV status or specific ED-BFN-H scores, supporting a biomarker-agnostic development plan.

Other Key Points:

• The company will present updated data at the Triple Meeting (Barcelona) in the near term to generate investigator enthusiasm.
• Management retains 100% of rights to the program and is not actively seeking a partner for the core program at this time, though they are open to dialogue to pressure-test strategy.
• The clinical trial design for the "headliner" study includes investigator choice of cetuximab, docetaxel, or methotrexate as the control arm to ensure global applicability.
• The primary endpoint for the Phase 3 trial is objective response rate (ORR) and overall survival (OS).